IL274083A - Diagnostic methods for anti-angiogenic agent therapy - Google Patents
Diagnostic methods for anti-angiogenic agent therapyInfo
- Publication number
- IL274083A IL274083A IL274083A IL27408320A IL274083A IL 274083 A IL274083 A IL 274083A IL 274083 A IL274083 A IL 274083A IL 27408320 A IL27408320 A IL 27408320A IL 274083 A IL274083 A IL 274083A
- Authority
- IL
- Israel
- Prior art keywords
- diagnostic methods
- angiogenic agent
- agent therapy
- therapy
- angiogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762575193P | 2017-10-20 | 2017-10-20 | |
US201862722671P | 2018-08-24 | 2018-08-24 | |
PCT/IB2018/058218 WO2019077593A1 (en) | 2017-10-20 | 2018-10-22 | Diagnostic methods for anti-angiogenic agent therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
IL274083A true IL274083A (en) | 2020-06-30 |
Family
ID=64564920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL274083A IL274083A (en) | 2017-10-20 | 2020-04-20 | Diagnostic methods for anti-angiogenic agent therapy |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210322574A1 (en) |
EP (1) | EP3697451A1 (en) |
JP (1) | JP2021500355A (en) |
CN (1) | CN111356480A (en) |
IL (1) | IL274083A (en) |
WO (1) | WO2019077593A1 (en) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
SI1325932T1 (en) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
US8039261B2 (en) | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US20100282634A1 (en) | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
US20070286845A1 (en) | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
EP2277887A3 (en) * | 2001-10-19 | 2011-02-16 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
ES2362931T3 (en) | 2002-03-04 | 2011-07-15 | Imclone Llc | SPECIFIC HUMAN ANTIBODIES AGAINST KDR AND USES OF THE SAME. |
CN102397542B (en) | 2004-11-18 | 2014-05-07 | 英克隆有限责任公司 | Antibodies against vascular endothelial growth factor receptor-1 |
BRPI0820298A8 (en) | 2007-11-09 | 2018-05-08 | Affitech Res As | anti-vegf antibody compositions and methods |
AU2011204405B2 (en) * | 2010-01-05 | 2015-06-18 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
SG10201500048SA (en) | 2010-01-05 | 2015-03-30 | Vascular Biogenics Ltd | Compositions and methods for treating glioblastoma gbm |
EA022941B1 (en) | 2010-10-18 | 2016-03-31 | Тотал Ресерч Энд Текнолоджи Фелюи | Process to increase the melt flow index of an expandable vinyl aromatic polymer |
LT2908865T (en) * | 2012-10-17 | 2019-01-10 | Vascular Biogenics Ltd. | Adenovirus expressing a fas-chimera and use thereof in cancer treatment methods |
WO2014118643A2 (en) * | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
-
2018
- 2018-10-22 JP JP2020522070A patent/JP2021500355A/en active Pending
- 2018-10-22 WO PCT/IB2018/058218 patent/WO2019077593A1/en unknown
- 2018-10-22 CN CN201880072851.3A patent/CN111356480A/en active Pending
- 2018-10-22 EP EP18811916.8A patent/EP3697451A1/en active Pending
- 2018-10-22 US US16/756,216 patent/US20210322574A1/en not_active Abandoned
-
2020
- 2020-04-20 IL IL274083A patent/IL274083A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN111356480A (en) | 2020-06-30 |
EP3697451A1 (en) | 2020-08-26 |
JP2021500355A (en) | 2021-01-07 |
US20210322574A1 (en) | 2021-10-21 |
WO2019077593A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201804141B (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
HK1248773A1 (en) | Therapeutic and diagnostic methods for cancer | |
HK1250376A1 (en) | Therapeutic and diagnostic methods for cancer | |
IL250685A0 (en) | Cytotoxicity-inducing therapeutic agent | |
EP3288455C0 (en) | Diagnostic methods | |
SG10202006688RA (en) | Bicyclic compounds for diagnosis and therapy | |
GB201513540D0 (en) | Therapeutic agents | |
IL247111A0 (en) | Preventive or therapeutic agent for kidney disease | |
GB201509893D0 (en) | Therapeutic agents | |
IL263205A (en) | Methods for making ultrasound contrast agents | |
GB201517263D0 (en) | Therapeutic agents | |
HK1251022A1 (en) | Diagnostic methods | |
PL3481933T3 (en) | Anti-greying agent | |
GB201509885D0 (en) | Therapeutic agents | |
GB201509888D0 (en) | Therapeutic agents | |
GB2556021B (en) | Medical apparatus | |
GB201615753D0 (en) | Diagnostic method | |
GB201513299D0 (en) | Therapeutic agents | |
GB201620641D0 (en) | Agent | |
SG11201700059WA (en) | Therapeutic agent for keratoconjunctive disorder | |
EP3535421C0 (en) | Diagnostic methods | |
IL274083A (en) | Diagnostic methods for anti-angiogenic agent therapy | |
PL3413712T3 (en) | Disinfection agent | |
GB201517264D0 (en) | Therapeutic agents | |
GB201702921D0 (en) | Therapeutic agent |